Tirzepatide: The Complete Guide to Weight Loss
Tirzepatide is the first dual GIP/GLP-1 receptor agonist — a next-generation weight loss medication that targets two hormonal pathways instead of one. In clinical trials, it produced significantly greater weight loss than semaglutide, making it the most effective FDA-approved weight loss medication currently available.
Key Facts at a Glance
- Drug class
- Dual GIP/GLP-1 receptor agonist
- Administration
- Once-weekly subcutaneous injection
- FDA approval
- November 2023 (Zepbound for weight loss)
- Average loss
- ~22.5% body weight (72 wks, SURMOUNT-1)
- Manufacturer
- Eli Lilly
- Available doses
- 2.5, 5, 7.5, 10, 12.5, and 15 mg
Table of Contents
What Is Tirzepatide?
Tirzepatide is a synthetic peptide developed by Eli Lilly that simultaneously activates two incretin hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). It's sold under two brand names:
- MounjaroFDA-approved for type 2 diabetes
- ZepboundFDA-approved for chronic weight management (November 2023)
How Does Tirzepatide Work?
Tirzepatide is structurally based on the native GIP hormone sequence (39 amino acids) and engineered to activate both GIP and GLP-1 receptors. This dual mechanism is what sets it apart from semaglutide (which only targets GLP-1).
GLP-1 Receptor Activation
Suppresses appetite via hypothalamic signaling, delays gastric emptying (so you feel full longer), enhances glucose-dependent insulin secretion, and reduces glucagon secretion. These are the same pathways semaglutide uses.
GIP Receptor Activation — The Added Dimension
GIP enhances the appetite-suppressing effects of GLP-1, improves insulin sensitivity, may promote fat oxidation (burning stored fat more efficiently), and contributes to improved metabolic regulation. This is the dimension semaglutide is missing.
“Imbalanced” Agonism
Tirzepatide has a unique pharmacological profile: it binds to the GIP receptor with equal affinity to natural GIP, but binds the GLP-1 receptor about 5-fold weaker than natural GLP-1. Despite the weaker GLP-1 binding, the combination of both pathways produces superior weight loss — suggesting that GIP activation adds something the GLP-1 pathway alone can't deliver.
The net effect: Two hormonal pathways working together to suppress appetite, slow digestion, improve insulin function, and enhance fat metabolism — producing significantly more weight loss than GLP-1-only medications.
Clinical Trial Evidence
Tirzepatide's weight loss efficacy has been studied in the SURMOUNT trial program — and most recently in a direct head-to-head trial against semaglutide.
SURMOUNT-1 — The Landmark Obesity Trial
Published
NEJM, 2022
Participants
2,539 adults
Duration
72 weeks
Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities, WITHOUT diabetes. Three tirzepatide doses vs. placebo.
| Dose | Avg. Loss | ≥5% Loss | ≥10% Loss | ≥20% Loss |
|---|---|---|---|---|
| 5 mg | 16.0% | 85% | 69% | 32% |
| 10 mg | 21.4% | 89% | 82% | 54% |
| 15 mg | 22.5% | 91% | 86% | 63% |
| Placebo | 3.1% | 35% | 14% | 1.3% |
For a 250-pound person on the highest dose, that's roughly 56 pounds lost over 72 weeks.
| Trial | Population | Avg. Loss | Key Finding |
|---|---|---|---|
| SURMOUNT-2 | Obesity + T2 diabetes | 14.7% | Strong results even with diabetes; still outperforms semaglutide |
| SURMOUNT-3 | After intensive lifestyle intervention | +21.1% | Added on top of lifestyle loss; total loss reached 26.6% |
| SURMOUNT-4 | Discontinuation study | — | Stopping = regaining ~14% body weight; weight loss maintained with continued use |
| SURMOUNT-5 | Head-to-head vs. semaglutide | 20.2% | 47% more weight loss than semaglutide (13.7%); published NEJM 2025 |
SURMOUNT-5: Head-to-Head vs. Semaglutide (2025)
Published
NEJM, 2025
Participants
751 adults
Duration
72 weeks
The first large-scale, randomized, head-to-head trial comparing tirzepatide directly to semaglutide. No placebo — both groups received active treatment at maximum tolerated doses.
| Metric | Tirzepatide | Semaglutide |
|---|---|---|
| Avg. weight loss | 20.2% | 13.7% |
| Avg. weight lost | 22.8 kg (50.3 lbs) | 15.0 kg (33.1 lbs) |
| Waist circumference | −18.4 cm | −13.0 cm |
| GI discontinuation rate | 2.7% | 5.6% |
Source: Aronne LJ, et al. N Engl J Med. 2025;393(1):26-36.
What the SURMOUNT trials tell us:
- Average loss of 22.5% at max dose — nearly one-quarter of body weight
- 63% of patients at 15 mg lost ≥20% of body weight
- Works even in patients with type 2 diabetes (though results are lower)
- Stacks powerfully with behavioral lifestyle changes
- Weight returns significantly when treatment stops
- Outperformed semaglutide by 47% in direct head-to-head trial
Dosing Protocol
Tirzepatide uses a gradual escalation over 20+ weeks, similar to semaglutide but with more dose steps. The 2.5 mg starting dose is for initiation only — it's not an effective maintenance dose.
Standard Zepbound Escalation Schedule
| Weeks | Weekly Dose | Purpose |
|---|---|---|
| 1–4 | 2.5 mg | Initiation only — NOT a maintenance dose |
| 5–8 | 5 mg | First maintenance dose option |
| 9–12 | 7.5 mg | Optional increase |
| 13–16 | 10 mg | Second maintenance dose option |
| 17–20 | 12.5 mg | Optional increase |
| 21+ | 15 mg | Maximum dose |
Important dosing notes:
- The 2.5 mg starting dose is for initiation only — minimum effective maintenance dose is 5 mg
- Many people achieve good results at 10 mg without needing 15 mg
- Each dose increase may temporarily worsen GI side effects
- Your doctor may keep you at a lower dose if you're responding well
- Inject subcutaneously: abdomen, thigh, or upper arm
- Same day each week, with or without food
Side Effects
Tirzepatide's side effect profile is similar to semaglutide, with mostly GI-related symptoms. Notably, in the SURMOUNT-5 head-to-head trial, fewer tirzepatide users discontinued due to GI side effects compared to semaglutide (2.7% vs. 5.6%).
Common Side Effects (>10% of patients)
- NauseaMost common; peaks during dose escalation
- Diarrhea
- Decreased appetitePartly how it works
- Vomiting
- Constipation
- Abdominal pain
Less Common Side Effects (1–10%)
- •Indigestion / heartburn
- •Burping / flatulence
- •Injection site reactions
- •Fatigue
- •Hair thinning (rapid weight loss)
- •Dizziness
Serious Side Effects (Rare but Important)
- Pancreatitis — Seek immediate care for severe, persistent abdominal pain
- Gallbladder problems — Rapid weight loss increases gallstone risk
- Kidney injury — Usually from dehydration due to vomiting/diarrhea
- Hypoglycemia — Risk increases if combined with insulin or sulfonylureas
- Allergic reactions — Rare; discontinue and seek care if they occur
FDA Black Box Warning
Like semaglutide, tirzepatide carries a black box warning for thyroid C-cell tumors based on rodent studies. Contraindicated in people with personal/family history of medullary thyroid carcinoma or MEN 2 syndrome.
Cost & Access
| Option | Brand | Typical Cost/Month |
|---|---|---|
| Zepbound (weight loss) | Eli Lilly | ~$1,069 list price |
| Zepbound (savings card) | Eli Lilly | As low as $25 |
| Mounjaro (diabetes) | Eli Lilly | Similar to Zepbound |
| Compounded tirzepatide | Various providers | $349–$699 |
How to Access Tirzepatide
- Talk to your doctor or use a telehealth platform
- Eligible criteria: BMI ≥30, or ≥27 with a weight-related condition
- If prescribed, fill through pharmacy or telehealth partner
- Check Eli Lilly's savings programs — significant discounts available for commercially insured patients
Compounded tirzepatide is available through telehealth providers during FDA shortage periods. Legal status is evolving — choose providers using FDA-registered compounding pharmacies.
Tirzepatide vs. Semaglutide: Quick Comparison
| Tirzepatide | Semaglutide | |
|---|---|---|
| Mechanism | GLP-1 + GIP (dual) | GLP-1 only |
| Avg. Weight Loss (head-to-head) | 20.2% | 13.7% |
| Max Dose | 15 mg/week | 2.4 mg/week (7.2 mg HD) |
| Brand Names | Mounjaro, Zepbound | Ozempic, Wegovy |
| GI Discontinuation Rate | 2.7% | 5.6% |
| FDA Approved (Weight Loss) | ✅ Nov 2023 | ✅ Jun 2021 |
Frequently Asked Questions
Is tirzepatide better than semaglutide?
In the SURMOUNT-5 head-to-head trial, tirzepatide produced 47% more weight loss than semaglutide (20.2% vs. 13.7%) with fewer GI-related discontinuations. For most people, tirzepatide appears to be the more effective option. However, individual responses vary, and semaglutide works well for many people. Cost, insurance coverage, and availability may also factor into the decision.
How quickly does tirzepatide work?
Most people notice reduced appetite within the first 2 weeks. Significant weight loss becomes visible by weeks 4–8. The most rapid weight loss occurs in the first 6–9 months.
What happens when I stop taking tirzepatide?
The SURMOUNT-4 trial showed significant weight regain after stopping — participants who switched to placebo regained 14.0% body weight. Like semaglutide, tirzepatide is currently considered a chronic (ongoing) treatment.
Can I switch from semaglutide to tirzepatide?
Yes, many people switch. Your doctor will typically start tirzepatide at 2.5 mg regardless of your previous semaglutide dose. Discuss the transition with your prescriber.
Does insurance cover tirzepatide for weight loss?
Coverage is improving but inconsistent. Eli Lilly's savings card can reduce costs to as low as $25/month for commercially insured patients. Check with your specific plan.
Is tirzepatide available as a pill?
Currently, tirzepatide is injection-only. Eli Lilly has oral formulations in development but none are approved yet.
The Bottom Line
Tirzepatide represents the current gold standard in FDA-approved weight loss medications. Its dual GIP/GLP-1 mechanism delivers significantly more weight loss than semaglutide — confirmed in a head-to-head trial published in the New England Journal of Medicine.
With average weight loss exceeding 20% of body weight and a generally favorable side effect profile, tirzepatide has set a new benchmark. The main barriers remain cost and access, though compounded versions and insurance coverage are expanding. For people who haven't responded adequately to semaglutide, or who want the most effective currently approved option, tirzepatide is the leading choice.
Sources
- 1.Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022;387(4):327-340.
- 2.Garvey WT, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)." Lancet. 2023;402(10402):613-626.
- 3.Wadden TA, et al. "Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3)." Nat Med. 2024;30:735-744.
- 4.Aronne LJ, et al. "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4)." JAMA. 2024;331(1):38-48.
- 5.Aronne LJ, et al. "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)." N Engl J Med. 2025;393(1):26-36.
- 6.Thomas MK, et al. "Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist." JCI Insight. 2020;5(17):e140532.
- 7."Tirzepatide - StatPearls." NCBI Bookshelf. Updated 2024.